Quest Diagnostics (DGX) Announces $750M Senior Note Shelf
More News related to DGX
- Quest Diagnostics to Speak at the UBS Global Healthcare Services Conference
- Health Discovery Corporation Partners with Major New York City Pancreatic Cancer Center to Develop a New Molecular Diagnostic Test for the Early Detection of Pancreatic Cancer
- Deutsche Bank Downgrades Quest Diagnostics (DGX) to Hold; Lowers 2010-11 EPS Estimates
- Highlights From DGX's Q4 Conference Call: Revenues Up 2.7%, EPS Grew 11%; Guides In-line for FY10
- Quest Diagnostics (DGX) Increases Stock Buyback to $750M
More News related to Equity Offerings
- Hoku Scientific (HOKU) Files 20.01M Common Shelf for a Selling Shareholder
- China Agritech (CAGC) Files $100M Mixed Securities Shelf
- ChinaTel Group (CHTL) Jumps Higher On 'Above-Market' Equity Financing
- Developers Diversified Realty (DDR) Prices 37.3M Common Offering at $8.16/Share
- EV Energy Partners (EVEP) Prices 3M Common Unit Offering at $28.08/Unit
Quest Diagnostics Incorporated (NYSE: DGX) announced today that it intends to offer $750,000,000 in aggregate principal amount in two series of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions. The notes will be fully and unconditionally guaranteed on a senior, unsecured basis by certain of the Company's domestic, wholly owned subsidiaries.
The issuance of the notes will be subject to customary closing conditions. The Company intends to use the net proceeds from the offering to repurchase any notes tendered under its concurrent tender offer, and for general corporate purposes, including acquisitions, capital expenditures, share repurchases and repayment of other indebtedness.
BofA Merrill Lynch, Morgan Stanley, RBS and Wells Fargo Securities will be joint book-running managers for the debt offering.
Related Categories
Equity OfferingsStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
